Cargando…
Biosimilar medicines and cost-effectiveness
Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to introduce and describe specific issues related to the economic evaluation of biosimilars by focusing on the relative costs, relative effectiveness, and cost-effectiveness of bi...
Autor principal: | Simoens, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169973/ https://www.ncbi.nlm.nih.gov/pubmed/21935330 http://dx.doi.org/10.2147/CEOR.S12494 |
Ejemplares similares
-
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021) -
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019) -
Tendering and biosimilars: what role for value-added services?
por: Simoens, Steven, et al.
Publicado: (2019) -
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020) -
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)